MC

574.3

-0.24%↓

SANES

6.359

+0.03%↑

BNP

77.66

-1.02%↓

CS.FR

40.33

+0.88%↑

ALV

356.5

-0.06%↓

MC

574.3

-0.24%↓

SANES

6.359

+0.03%↑

BNP

77.66

-1.02%↓

CS.FR

40.33

+0.88%↑

ALV

356.5

-0.06%↓

MC

574.3

-0.24%↓

SANES

6.359

+0.03%↑

BNP

77.66

-1.02%↓

CS.FR

40.33

+0.88%↑

ALV

356.5

-0.06%↓

MC

574.3

-0.24%↓

SANES

6.359

+0.03%↑

BNP

77.66

-1.02%↓

CS.FR

40.33

+0.88%↑

ALV

356.5

-0.06%↓

MC

574.3

-0.24%↓

SANES

6.359

+0.03%↑

BNP

77.66

-1.02%↓

CS.FR

40.33

+0.88%↑

ALV

356.5

-0.06%↓

Search

Evotec AG

Suletud

SektorRahandus

5.93 -3.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.74

Max

6.13

Põhinäitajad

By Trading Economics

Sissetulek

55M

-40M

Müük

2.8M

185M

Kasumimarginaal

-21.437

Töötajad

5,007

EBITDA

58M

-45M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+111.22% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

17. apr 2025

Turustatistika

By TradingEconomics

Turukapital

1.1B

Eelmine avamishind

9.19

Eelmine sulgemishind

5.93

Uudiste sentiment

By Acuity

34%

66%

114 / 542 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Evotec AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuni 2024, 13:17 UTC

Market Talk

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Evotec AG Prognoos

Hinnasiht

By TipRanks

111.22% tõus

12 kuu keskmine prognoos

Keskmine 12.8 EUR  111.22%

Kõrge 14 EUR

Madal 11.6 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Evotec AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.075 / 6.395Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

114 / 542 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.